Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

IMDYLLTRA 1 milligram powder for concentrate and solution for solution for infusion {equilateral_black_triangle}

Active Ingredient:
Tarlatamab
Company:  
Amgen Ltd See contact details
ATC code: 
L01FX33
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials
{arrow_left}
{arrow_right}
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine.
{info_black}
Last updated on emc: 06 Jan 2026

{equilateral_black_triangle} This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

{pdf} View or print the patient leaflet as PDF

Below is a text only representation of the Patient Information Leaflet (ePIL).

The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on {phone} 0800 198 5000. The product code(s) for this leaflet is: PLGB 13832/0083.

{printer} Print patient leaflet as text only

IMDYLLTRA 1 mg and 10 mg powder for concentrate and solution for solution for infusion

Package leaflet: Information for the patient

IMDYLLTRA 1 mg powder for concentrate and solution for solution for infusion

IMDYLLTRA 10 mg powder for concentrate and solution for solution for infusion

tarlatamab

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist or nurse.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What IMDYLLTRA is and what it is used for
2. What you need to know before you use IMDYLLTRA
3. How to use IMDYLLTRA
4. Possible side effects
5. How to store IMDYLLTRA
6. Contents of the pack and other information

1. What IMDYLLTRA is and what it is used for

The active ingredient in IMDYLLTRA is tarlatamab. This belongs to a group of medicines called antineoplastic agents which target cancer cells.

IMDYLLTRA is used to treat adults with small cell lung cancer (SCLC) that has spread throughout the lungs and/or to other parts of the body.

IMDYLLTRA can only be prescribed if you have previously been treated with chemotherapy that contains platinum, and it did not work or is no longer working.

How does IMDYLLTRA work?

IMDYLLTRA is different to chemotherapy. IMDYLLTRA works with your immune system to find and destroy small cell lung cancer cells.

If you have any questions about how IMDYLLTRA works or why this medicine has been prescribed for you, ask your doctor, pharmacist or nurse.

2. What you need to know before you use IMDYLLTRA
Do not use IMDYLLTRA
  • if you are allergic to tarlatamab or any of the other ingredients of this medicine (listed in section 6).
  • if you have not previously been treated with two other types of treatments which did not or are no longer working.
  • in children under 18 years of age (see details below).
  • breast-feeding or planning to breast-feed (see details below).
  • if the medicine is past its expiry date (see section 5).

If you are not sure, talk to your doctor, pharmacist or nurse before you are given IMDYLLTRA.

Warnings and precautions

Tarlatamab may cause serious side-effects such as shown below. If you have any questions, talk to your doctor before you are given IMDYLLTRA.

Tell your doctor, pharmacist or nurse immediately if you experience any of the following while receiving IMDYLLTRA as they may need to treat the symptoms:

  • Cytokine release syndrome (CRS) is when your body releases substances called cytokines into the blood. CRS is common and can be serious or life-threatening. Tell your doctor or get medical help immediately if you experience any signs and symptoms of CRS, including:
    • fever
    • low blood pressure (hypotension)
    • shortness of breath, trouble breathing
    • fast or irregular heartbeat: palpitations, dizziness
    • headache
    • chills
    • nausea
    • vomiting
  • Immune effector cell-associated neurotoxicity syndrome (ICANS) is a syndrome of brain and nervous system that can cause brain related (neurologic) problems, which can be serious or life-threatening. These problems may happen days or weeks after you receive tarlatamab. Your doctor may refer you to a doctor who specialises in neurologic problems. Tell your doctor or get medical help immediately if you experience any signs or symptoms of neurologic problems, including:
    • trouble speaking, memory loss, personality changes (encephalopathy)
    • confusion
    • feeling disoriented or having difficulty thinking clearly (delirium)
    • seizure
    • loss of balance or coordination (ataxia)
    • weakness or numbness of arms and legs (neurotoxicity)
    • shakiness of your hands or limbs (tremor)
    • headache
    • Tiredness or feeling sleepy
  • low white blood cell counts (neutropenia, lymphopenia):
    • chills or shivering
    • feel warm
    • high body temperature
  • Allergic reactions (hypersensitivity) including but not limited to the following:
    • rash
    • difficulty breathing

Your doctor or nurse will monitor for signs and symptoms of these reactions during and after the infusion and will inform you and your caregiver about the signs and symptoms of CRS and ICANS.

Children and adolescents

IMDYLLTRA has not been studied in children or adolescents. Treatment with IMDYLLTRA is not recommended in patients under 18 years of age.

Other medicines and IMDYLLTRA

Tell your doctor, pharmacist, or nurse if you are taking, have recently taken or might take any other medicines.

Pregnancy and breast-feeding

The effects of IMDYLLTRA in pregnant women are not known.

Tell your doctor or nurse if you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby. Your doctor will help you weigh the benefits against the risk of taking IMDYLLTRA while you are pregnant.

Tell your doctor or nurse if you become pregnant during treatment with IMDYLLTRA. Your doctor may need to talk to you about potential risks.

Women who are able to become pregnant should use effective contraception during treatment and for at least 2 months after your last dose. Talk to your doctor or nurse about suitable methods of contraception.

It is not known whether the ingredients of IMDYLLTRA pass into breast milk. Tell your doctor or nurse if you are breast-feeding or are planning to breast-feed. You should not breast-feed during treatment with IMDYLLTRA and for at least 2 months after your last dose.

Driving and using machines

If you experience symptoms such as dizziness, seizures and confusion following IMDYLLTRA infusion, refrain from driving, and operating heavy or potentially dangerous machinery and engaging in hazardous occupations or activities until symptoms resolve.

3. How to use IMDYLLTRA

Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

How IMDYLLTRA is given

IMDYLLTRA will be given to you by your doctor or nurse through a vein (intravenous) as a 1 hour infusion.

You will receive a smaller dose of 1 mg IMDYLLTRA on Day 1.

You will receive the full treatment dose of 10 mg IMDYLLTRA on Day 8, Day 15 and then every 2 weeks thereafter.

Within one hour before receiving your first two doses of IMDYLLTRA, you will be given a class of medicine called corticosteroids to help reduce your risk of CRS. This will be given to you by intravenous (IV) infusion into your vein. You may also get IV fluids after your first two doses of IMDYLLTRA.

Your doctor will monitor you for 16 hours after the first infusion of IMDYLLTRA on Day 1). Your doctor will monitor you for signs and symptoms of CRS and neurologic problems during treatment with IMDYLLTRA, as well as other side effects, and treat you as needed. You may be hospitalised if you develop signs or symptoms of CRS or neurologic problems during treatment with IMDYLLTRA.

You should plan to stay within 1 hour travel time of the hospital for 24 hours from the start of each IMDYLLTRA infusion on Day 1 and Day 8 and have a caregiver with you.

After the third infusion (Day 15), and for all future infusions your doctor will provide information about how long you may need to be monitored after the infusion of IMDYLLTRA.

Your doctor will determine how long you should stay on IMDYLLTRA.

Your doctor may delay or completely stop treatment with IMDYLLTRA if you develop CRS, neurologic problems, or any other side effects that are severe.

You and your caregiver will be provided a Patient Alert Card (PAC) which contains instructions on the signs and symptoms of Cytokine Release Syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Tell your doctor immediately if you get any of the following or combination of the following side effects:

  • sudden and severe inflammatory syndrome with symptoms including fever, chills, low blood oxygen, headache, decreased blood pressure, nausea, or vomiting - these may be signs of a so-called cytokine release syndrome (CRS).
  • neurologic events: shaking (or tremor), confusion, disturbances of brain function (encephalopathy), difficulty in communicating (aphasia), seizure (convulsion) – these may be signs of a so-called immune effector cell-associated neurotoxicity syndrome (ICANS).

Other side effects include:

Very common side effects (may affect more than 1 in 10 people)

  • decreased appetite
  • bad taste in mouth (dysgeusia)
  • fever (pyrexia)
  • constipation
  • decreased levels of red blood cells (anaemia)
  • tiredness (fatigue)
  • nausea
  • physical weakness or lack of energy (asthenia)
  • low level of sodium in blood (hyponatremia)
  • headache
  • decreased levels of types of white blood cells (neutropenia, lymphopenia, neutrophil count decrease)
  • dry or wet cough, shortness of breath (dyspnea)
  • decreased weight

Common (may affect up to 1 in 10 people):

  • neurologic problems (Immune effector cell-associated neurotoxicity syndrone (ICANS))
  • confusion (confusional state)
  • shakiness of hands and limbs (tremor)
  • feeling disoriented (delirium)

Uncommon (may affect up to 1 in 100 people):

  • change in normal activity of nervous system (neurotoxicity)
  • seizure
  • loss of balance or coordination (ataxia)
  • speaking, memory loss, personality changes (encephalopathy)

Reporting of side effects

If you get any side effects, talk to your doctor or, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can help provide more information on the safety of this medicine.

Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard

or search for MHRA Yellow Card in the Google Play or Apple App Store

5. How to store IMDYLLTRA

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.

Unopened Vials

  • Store and transport refrigerated (2°C - 8°C).
  • Do not freeze.
  • Store in the original carton in order to protect from light.

Prepared IMDYLLTRA (infusion bag)

  • Once at room temperature 20°C to 25°C, store no longer than 8 hours.
  • When refrigerated (2°C to 8°C), the infusion bag must be used within 7 days.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information
What IMDYLLTRA contains
  • The active substance is tarlatamab.
  • The other ingredients are sucrose, polysorbate 80, L-glutamic acid, and sodium hydroxide.
  • The IV Solution Stabiliser contains citric acid monohydrate, lysine hydochloride, polysorbate 80, sodium hydroxide and water for injection.

What IMDYLLTRA looks like and contents of the pack

IMDYLLTRA is a powder for concentrate and solution for infusion.

  • 1 mg pack contains: 1 glass vial of 1 mg IMDYLLTRA and 2 vials of 7 mL IV Solution Stabiliser.
  • 10 mg pack contains: 1 glass vial of 10 mg IMDYLLTRA and 2 vials of 7 mL IV Solution Stabiliser.

Sterile Water for Injection (not included) should be used to reconstitute IMDYLLTRA.

Marketing Authorisation Holder
Amgen Limited
216 Cambridge Science Park
Milton Road
Cambridge
CB4 0WA
United Kingdom

Manufacturer
Amgen Europe B.V.
Minervum 7061
4817 ZK Breda
The Netherlands

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

Amgen Limited
Tel: +44 (0)1223 420305

This leaflet was last revised in December 2025.

Amgen Ltd
Company image
Address
216 Cambridge Science Park, Milton Road, Cambridge, CB4 0WA, UK
Telephone
+44 (0)1223 420 305
Fax
+44 (0)1223 426 314
Medical Information Direct Line
+44 (0)1223 436 441
Medical Information e-mail
[email protected]
Medical Information Fax
+44 (0)1223 426 314